Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease
AUTOR(ES)
Bhattaram, Venkatesh Atul
FONTE
Springer US
RESUMO
Parkinson’s disease is an age-related degenerative disorder of the central nervous system that often impairs the sufferer’s motor skills and speech, as well as other functions. Symptoms can include tremor, stiffness, slowness of movement, and impaired balance. An estimated four million people worldwide suffer from the disease, which usually affects people over the age of 60. Presently, there is no precedent for approving any drug as having a modifying effect (i.e., slowing or delaying) for disease progression of Parkinson’s disease. Clinical trial designs such as delayed start and withdrawal are being proposed to discern symptomatic and protective effects. The current work focused on understanding the features of delayed start design using prior knowledge from published and data submitted to US Food and Drug Administration (US FDA) as part of drug approval or protocol evaluation. Clinical trial simulations were conducted to evaluate the false-positive rate, power under a new statistical analysis methodology, and various scenarios leading to patient discontinuations from clinical trials. The outcome of this work is part of the ongoing discussion between the US FDA and the pharmaceutical industry on the standards required for demonstrating disease-modifying effect using delayed start design.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2758116Documentos Relacionados
- Evidence for early disease-modifying drugs in rheumatoid arthritis
- Glucosamine: A potential disease-modifying agent in osteoarthritis?
- Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review
- Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes
- Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers